VIRX vs. GANX, IPA, ELDN, SURF, PPBT, VINC, CMMB, PRDS, LBPH, and LTRN
Should you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include Gain Therapeutics (GANX), ImmunoPrecise Antibodies (IPA), Eledon Pharmaceuticals (ELDN), Surface Oncology (SURF), Purple Biotech (PPBT), Vincerx Pharma (VINC), Chemomab Therapeutics (CMMB), Pardes Biosciences (PRDS), Longboard Pharmaceuticals (LBPH), and Lantern Pharma (LTRN). These companies are all part of the "medical" sector.
Viracta Therapeutics vs.
Viracta Therapeutics (NASDAQ:VIRX) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk, community ranking and profitability.
Viracta Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500.
In the previous week, Gain Therapeutics had 5 more articles in the media than Viracta Therapeutics. MarketBeat recorded 5 mentions for Gain Therapeutics and 0 mentions for Viracta Therapeutics. Gain Therapeutics' average media sentiment score of 0.69 beat Viracta Therapeutics' score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the news media.
Viracta Therapeutics received 4 more outperform votes than Gain Therapeutics when rated by MarketBeat users. Likewise, 67.74% of users gave Viracta Therapeutics an outperform vote while only 54.84% of users gave Gain Therapeutics an outperform vote.
25.8% of Viracta Therapeutics shares are held by institutional investors. Comparatively, 10.0% of Gain Therapeutics shares are held by institutional investors. 7.4% of Viracta Therapeutics shares are held by insiders. Comparatively, 11.0% of Gain Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Viracta Therapeutics' return on equity of -106.11% beat Gain Therapeutics' return on equity.
Gain Therapeutics has higher revenue and earnings than Viracta Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Viracta Therapeutics presently has a consensus target price of $9.50, suggesting a potential upside of 726.09%. Gain Therapeutics has a consensus target price of $9.20, suggesting a potential upside of 175.45%. Given Viracta Therapeutics' higher probable upside, research analysts plainly believe Viracta Therapeutics is more favorable than Gain Therapeutics.
Summary
Viracta Therapeutics beats Gain Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Viracta Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VIRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Viracta Therapeutics Competitors List
Related Companies and Tools